Li W, Zhao J, Hu N, Zhang W
Front Psychiatry. 2025; 16:1537418.
PMID: 39980982
PMC: 11839625.
DOI: 10.3389/fpsyt.2025.1537418.
Fritze S, Brandt G, Volkmer S, Daub J, Altinok D, Kubera K
Schizophrenia (Heidelb). 2025; 11(1):16.
PMID: 39939637
PMC: 11821994.
DOI: 10.1038/s41537-024-00547-0.
da Rosa A, da Costa M, Sorato G, Manjabosco F, de Bem E, Dellazari L
JMIR Res Protoc. 2025; 14:e58031.
PMID: 39883920
PMC: 11826951.
DOI: 10.2196/58031.
Davis L, Behl S, Lee D, Zeng H, Skubiak T, Weaver S
JAMA Psychiatry. 2024; 82(3):218-227.
PMID: 39693081
PMC: 11883513.
DOI: 10.1001/jamapsychiatry.2024.3996.
Peretzke R, Neher P, Brandt G, Fritze S, Volkmer S, Daub J
Mol Psychiatry. 2024; .
PMID: 39623072
DOI: 10.1038/s41380-024-02821-0.
Cariprazine-Induced Extrapyramidal Symptoms and a Rare Downward Eye Deviation in Oculogyric Crisis: A Case Series.
Basera D, Sutar R, Kaur G, Modak T
Indian J Psychol Med. 2024; :02537176241252710.
PMID: 39564314
PMC: 11572596.
DOI: 10.1177/02537176241252710.
Risperidone ISM: review and update of its usefulness in all phases of schizophrenia.
Messer T, Bernardo M, Anta L, Martinez-Gonzalez J
Ther Adv Psychopharmacol. 2024; 14:20451253241280046.
PMID: 39421638
PMC: 11483852.
DOI: 10.1177/20451253241280046.
Effects of sodium benzoate on cognitive function in neuropsychiatric disorders: a systematic review and meta-analysis.
Liang C, Cheng H, Tseng M
Front Psychiatry. 2024; 15:1370431.
PMID: 39315325
PMC: 11416944.
DOI: 10.3389/fpsyt.2024.1370431.
Prevalence of spontaneous movement disorders (dyskinesia, parkinsonism, akathisia and dystonia) in never-treated patients with chronic and first-episode psychosis: a systematic review and meta-analysis.
Kalniunas A, James K, Pappa S
BMJ Ment Health. 2024; 27(1).
PMID: 39313255
PMC: 11418527.
DOI: 10.1136/bmjment-2024-301184.
ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment.
Bugarski-Kirola D, Bitter I, Liu I, Abbs B, Stankovic S
Schizophr Bull Open. 2024; 3(1):sgac006.
PMID: 39144794
PMC: 11205884.
DOI: 10.1093/schizbullopen/sgac006.
Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study.
Caligiuri M, Weiden P, Legedza A, Yagoda S, Claxton A
Schizophr Bull Open. 2024; 3(1):sgac018.
PMID: 39144789
PMC: 11205961.
DOI: 10.1093/schizbullopen/sgac018.
Sulforaphane Effects on Cognition and Symptoms in First and Early Episode Schizophrenia: A Randomized Double-Blind Trial.
Hei G, Smith R, Li R, Ou J, Song X, Zheng Y
Schizophr Bull Open. 2024; 3(1):sgac024.
PMID: 39144775
PMC: 11205988.
DOI: 10.1093/schizbullopen/sgac024.
Extrapyramidal side effects with nonantipsychotic medications.
Koch J, Launio M, Williams A
Ment Health Clin. 2024; 14(4):233-235.
PMID: 39104434
PMC: 11298035.
DOI: 10.9740/mhc.2024.08.233.
Effectiveness of pharmacological treatments for severe agitation in real-world emergency settings: protocol of individual-participant-data network meta-analysis.
Siafis S, Wu H, Nomura N, Schneider-Thoma J, Bighelli I, Lorenz C
Syst Rev. 2024; 13(1):205.
PMID: 39095865
PMC: 11295517.
DOI: 10.1186/s13643-024-02623-z.
Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies.
Calisti F, Tocco M, Mao Y, Goldman R
Ann Gen Psychiatry. 2024; 23(1):26.
PMID: 39020362
PMC: 11256627.
DOI: 10.1186/s12991-024-00502-4.
Comparative Study of Extrapyramidal Side Effects, Sexual Dysfunctions and Hyperprolactinaemia Using Typical and Atypical Antipsychotic Medications Among Patients with Schizophrenia in Maiduguri.
Shettima F, Wakil M, Sheikh T, Rabbebe I, Abdulaziz M, Jidda S
Niger Med J. 2024; 64(5):612-626.
PMID: 38962106
PMC: 11218855.
DOI: 10.60787/NMJ-64-5-311.
Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders.
Ibragimov K, Keane G, Carreno Glaria C, Cheng J, Llosa A
Cochrane Database Syst Rev. 2024; 7:CD013425.
PMID: 38958149
PMC: 11220909.
DOI: 10.1002/14651858.CD013425.pub2.
Exploring the interplay of psychiatric symptoms, antipsychotic medications, side effects, employment status, and quality of life in Chronic Schizophrenia.
Zhou D, Yang X, Wang W, Jin W, Tang Y, Zheng Z
BMC Psychiatry. 2024; 24(1):484.
PMID: 38956530
PMC: 11220993.
DOI: 10.1186/s12888-024-05929-3.
Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia.
Galbally M, Wynter K, Siskind D, Correll C, Northwood K, Every-Palmer S
CNS Drugs. 2024; 38(7):559-570.
PMID: 38713452
PMC: 11182865.
DOI: 10.1007/s40263-024-01089-w.
Clinical and Sociodemographic Correlations with Neurological Soft Signs in Hospitalized Patients with Schizophrenia: A Preliminary Longitudinal Study.
Petrescu C, Mihalache O, Vilciu C, Petrescu D, Marian G, Ciobanu C
Biomedicines. 2024; 12(4).
PMID: 38672143
PMC: 11048323.
DOI: 10.3390/biomedicines12040787.
